or Try an Advanced Search...

    ETF Components for HRTS - Tema Cardiovascular and Metabolic ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LLY F -0.90 6.44
    VRTX D -0.35 5.64
    AMGN D 0.57 5.11
    ALNY D -0.68 4.95
    CRNX B 1.50 4.00
    BBIO F 1.04 3.69
    CYTK D -3.22 3.47
    BSX A 1.63 2.99
    ASND F -1.14 2.88
    MDT D 0.57 2.79
    MIRM B 0.32 2.60
    DXCM C -0.57 2.57
    MREO F 2.37 2.49
    IONS F -4.38 2.42
    MASI B 2.83 2.39
    REGN F 0.36 2.37
    KROS D 2.07 2.10
    EW C 1.55 1.91
    MLYS F -4.62 1.89
    PODD B -1.38 1.88
    RCKT F -0.08 1.80
    ARWR D -1.70 1.76
    RARE F 0.24 1.71
    NTLA F 5.11 1.66
    MDGL C 3.91 1.46
    WST C 2.48 1.43
    AKRO C 1.06 1.28
    NVS D 0.49 1.26
    VKTX F 1.16 1.14
    NARI C 2.12 0.97
    EWTX C 0.67 0.96
    SLN F 9.54 0.91
    TERN F 2.41 0.70
    VERV D 1.76 0.64
    TNYA C -2.70 0.43
    RANI F -0.98 0.31

    Represented by ETF Holdings

    Keywords: Medicine Biopharmaceutical Biotechnology S&P 500 Diabetes Organ Systems Cholesterol Disease Obesity Amyloid Bone Endocrine System Hypertension Amyloidosis Catheter Clinical Development Heart Failure Hypercholesterolemia Insulin Life Sciences
    Industries: Biotechnology Medical Devices Drug Manufacturers - Major Medical Instruments & Supplies Diagnostics & Research

    Recent News for Tema Cardiovascular and Metabolic ETF & its Holdings

    Date Stock Title
    Nov 21 AMGN Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 LLY Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
    Nov 21 NVS Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
    Nov 21 NVS Novartis buys gene therapy developer Kate for up to $1.1B
    Nov 21 MDT Here's Why Medtronic (MDT) is a Strong Value Stock
    Nov 21 DXCM 3 US Stocks Estimated To Be Trading At Discounts Of Up To 39.3%
    Nov 21 PODD Insulet adds Abbott’s FreeStyle Libre 2 Plus to Omnipod 5’s compatibility roster
    Nov 21 PODD Insulet: Superb Business Growth, Starting Valuations Outsized Risk
    Nov 21 NVS Novartis raises mid-term sales guidance
    Nov 21 MDT 3 Dividend Stocks I'll Never Sell
    Nov 21 NVS Novartis Lifts Midterm Sales Guidance Amid U.S. Expansion
    Nov 21 NVS Novartis wagers more than $1B on gene therapies for the nervous system
    Nov 21 AMGN Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares
    Nov 21 MDT Medtronic’s insulin pen app gains FDA clearance
    Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
    Nov 21 AMGN Amgen picks prolific biotech founder Chang as new top scientist
    Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 21 AMGN Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 21 NVS Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
    Nov 20 PODD Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund advisor generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
    Investment Management Cardiovascular Disease Metabolic Disease Treatment Of Cardiovascular Diseases
    Back to the Main HRTS Page...